Actinium Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration with UC Davis in Ongoing Clinical Trial for Patients with HIV-Related Lymphoma
- Monday, January 13, 2020, 7:14
- PR Newswire
- Add a comment
NEW YORK, Jan. 13, 2020 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium”), announced today that it has entered into an agreement with the University of California, Davis (UC Davis) to utilize Actinium’s Antibody Radiation-Conjugate or ARC apamistamab-I-131…
About the Author
admin has written 21810 stories on this site.